Berthold A Nock

List of Publications by Year
in descending order

51 papers	1,677 citations	293460 24 h-index	325983 40 g-index
51 all docs	51 docs citations	51 times ranked	1256 citing authors

#	Article	IF	Citations
1	Peptide radiopharmaceuticals for targeted diagnosis & therapy of human tumors. , 2022, , .		0
2	Gamma camera imaging by radiolabeled gastrin/cholecystokinin analogs. , 2022, , .		0
3	Nonpeptidic Z360-Analogs Tagged with Trivalent Radiometals as Anti-CCK2R Cancer Theranostic Agents: A Preclinical Study. Pharmaceutics, 2022, 14, 666.	2.0	3
4	GRPr Antagonist ⁶⁸Ga-SB3 PET/CT Imaging of Primary Prostate Cancer in Therapy-NaÃ¯ve Patients. Journal of Nuclear Medicine, 2021, 62, 1517-1523.	2.8	17
5	[99mTc]Tc-DB15 in GRPR-Targeted Tumor Imaging with SPECT: From Preclinical Evaluation to the First Clinical Outcomes. Cancers, 2021, 13, 5093.	1.7	14
6	Radiolabeled Bombesin Analogs. Cancers, 2021, 13, 5766.	1.7	34
7	Optimizing the Profile of [99mTc]Tcâ€“NT(7â€“13) Tracers in Pancreatic Cancer Models by Means of Protease Inhibitors. International Journal of Molecular Sciences, 2020, 21, 7926.	1.8	7
8	[99mTc]Tc-DB1 Mimics with Different-Length PEG Spacers: Preclinical Comparison in GRPR-Positive Models. Molecules, 2020, 25, 3418.	1.7	8
9	One Step Closer to Clinical Translation: Enhanced Tumor Targeting of [99mTc]Tc-DB4 and [111In]In-SG4 in Mice Treated with Entresto. Pharmaceutics, 2020, 12, 1145.	2.0	9
10	Key-Protease Inhibition Regimens Promote Tumor Targeting of Neurotensin Radioligands. Pharmaceutics, 2020, 12, 528.	2.0	8
11	Instant kit preparation of 68Ga-radiopharmaceuticals via the hybrid chelator DATA: clinical translation of [68Ga]Ga-DATA-TOC. EJNMMI Research, 2019, 9, 48.	1.1	20
12	Theranostic approaches in nuclear oncology: From bench to bed. Journal of Labelled Compounds and Radiopharmaceuticals, 2019, 62, 612-614.	0.5	2
13	Trastuzumab cotreatment improves survival of mice with PCâ€3 prostate cancer xenografts treated with the GRPR antagonist ¹⁷⁷Luâ€DOTAGAâ€PEG₂â€RM26. International Journal of Cancer, 2019, 145, 3347-3358.	2.3	30
14	Comparing Gly11/dAla11-Replacement vs. the in-Situ Neprilysin-Inhibition Approach on the Tumor-targeting Efficacy of the 111In-SB3/111In-SB4 Radiotracer Pair. Molecules, 2019, 24, 1015.	1.7	11
15	Localization of 99mTc-GRP Analogs in GRPR-Expressing Tumors: Effects of Peptide Length and Neprilysin Inhibition on Biological Responses. Pharmaceuticals, 2019, 12, 42.	1.7	8
16	Comparative evaluation of the new GRPRâ€antagonist ¹¹¹Inâ€SB9 and ¹¹¹Inâ€AMBA in prostate cancer models: Implications of in vivo stability. Journal of Labelled Compounds and Radiopharmaceuticals, 2019, 62, 646-655.	0.5	10
17	Radiometal-Dependent Biological Profile of the Radiolabeled Gastrin-Releasing Peptide Receptor Antagonist SB3 in Cancer Theranostics: Metabolic and Biodistribution Patterns Defined by Neprilysin. Bioconjugate Chemistry, 2018, 29, 1774-1784.	1.8	27
18	In Vivo Stabilized SB3, an Attractive GRPR Antagonist, for Pre- and Intra-Operative Imaging for Prostate Cancer. Molecular Imaging and Biology, 2018, 20, 973-983.	1.3	13

#	Article	IF	Citations
19	New Gastrin Releasing Peptide Receptor-Directed [^{99m}Tc]Demobesin 1 Mimics: Synthesis and Comparative Evaluation. Journal of Medicinal Chemistry, 2018, 61, 3138-3150.	2.9	20
20	From Bench to Bed. PET Clinics, 2017, 12, 205-217.	1.5	29
21	Amide-to-triazole switch vs. in vivo NEP-inhibition approaches to promote radiopeptide targeting of GRPR-positive tumors. Nuclear Medicine and Biology, 2017, 52, 57-62.	0.3	14
22	Theranostic Prospects of Gastrin-Releasing Peptide Receptorâ€“Radioantagonists in Oncology. PET Clinics, 2017, 12, 297-309.	1.5	49
23	Novel bifunctional DATA chelator for quick access to site-directed PET ⁶⁸Ga-radiotracers: preclinical proof-of-principle with [Tyr³]octreotide. Dalton Transactions, 2017, 46, 14584-14590.	1.6	15
24	Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results. Journal of Nuclear Medicine, 2017, 58, 75-80.	2.8	129
25	⁶⁸Ga/¹⁷⁷Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist for Theranostic Use in Oncology. Journal of Nuclear Medicine, 2017, 58, 293-299.	2.8	98
26	NeoBOMB1, a GRPR-Antagonist for Breast Cancer Theragnostics: First Results of a Preclinical Study with [67Ga]NeoBOMB1 in T-47D Cells and Tumor-Bearing Mice. Molecules, 2017, 22, 1950.	1.7	32
27	In Vivo Stabilization of a Gastrin-Releasing Peptide Receptor Antagonist Enhances PET Imaging and Radionuclide Therapy of Prostate Cancer in Preclinical Studies. Theranostics, 2016, 6, 104-117.	4.6	53
28	99mTc-labeled gastrins of varying peptide chain length: Distinct impact of NEP/ACE-inhibition on stability and tumor uptake in mice. Nuclear Medicine and Biology, 2016, 43, 347-354.	0.3	15
29	Preclinical pharmacokinetics, biodistribution, radiation dosimetry and toxicity studies required for regulatory approval of a phase I clinical trial with 111In-CP04 in medullary thyroid carcinoma patients. European Journal of Pharmaceutical Sciences, 2016, 91, 236-242.	1.9	43
30	Impact of clinically tested NEP/ACE inhibitors on tumor uptake of [111In-DOTA]MG11â€”first estimates for clinical translation. EJNMMI Research, 2016, 6, 15.	1.1	23
31	Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [68Ga]SB3 and PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 964-973.	3.3	90
32	Improving the In Vivo Profile of Minigastrin Radiotracers: A Comparative Study Involving the Neutral Endopeptidase Inhibitor Phosphoramidon. Cancer Biotherapy and Radiopharmaceuticals, 2016, 31, 20-28.	0.7	24
33	In vivo inhibition of neutral endopeptidase enhances the diagnostic potential of truncated gastrin 111In-radioligands. Nuclear Medicine and Biology, 2015, 42, 824-832.	0.3	15
34	In Vitro and In Vivo Application of Radiolabeled Gastrin-Releasing Peptide Receptor Ligands in Breast Cancer. Journal of Nuclear Medicine, 2015, 56, 752-757.	2.8	49
35	In Vivo Enzyme Inhibition Improves the Targeting of [¹⁷⁷Lu]DOTA-GRP(13â€“27) in GRPR-Positive Tumors in Mice. Cancer Biotherapy and Radiopharmaceuticals, 2014, 29, 359-367.	0.7	9
36	â€œTo Serve and Protectâ€ Enzyme Inhibitors as Radiopeptide Escorts Promote Tumor Targeting. Journal of Nuclear Medicine, 2014, 55, 121-127.	2.8	101

#	Article	IF	Citations
37	[¹¹¹In-DOTA]LTT-SS28, a First Pansomatostatin Radioligand for in Vivo Targeting of Somatostatin Receptor-Positive Tumors. Journal of Medicinal Chemistry, 2014, 57, 6564-6571.	2.9	18
38	[DOTA]Somatostatin-14 analogs and their 111In-radioligands: Effects of decreasing ring-size on sst1â€“5 profile, stability and tumor targeting. European Journal of Medicinal Chemistry, 2014, 73, 30-37.	2.6	12
39	GRP Receptor Imaging of Prostate Cancer Using [99mTc]Demobesin 4: a First-in-Man Study. Molecular Imaging and Biology, 2014, 16, 888-895.	1.3	44
40	Tumor Diagnosis with New ¹¹¹In-Radioligands Based on Truncated Human Gastrin Releasing Peptide Sequences: Synthesis and Preclinical Comparison. Journal of Medicinal Chemistry, 2013, 56, 8579-8587.	2.9	13
41	Gastrin Releasing Peptide Receptor-Directed Radioligands Based on a Bombesin Antagonist: Synthesis, ¹¹¹In-Labeling, and Preclinical Profile. Journal of Medicinal Chemistry, 2013, 56, 2374-2384.	2.9	28
42	^{99m}Tc Radiotracers Based on Human GRP(18-27): Synthesis and Comparative Evaluation. Journal of Nuclear Medicine, 2013, 54, 1797-1803.	2.8	21
43	Tetraamine-Coupled Peptides and Resulting 99mTc-Radioligands: An Effective Route for Receptor-Targeted Diagnostic Imaging of Human Tumors. Current Topics in Medicinal Chemistry, 2013, 12, 2655-2667.	1.0	25
44	[^{99m}Tc]Demomedin C, a Radioligand Based on Human Gastrin Releasing Peptide(18-27): Synthesis and Preclinical Evaluation in Gastrin Releasing Peptide Receptor-Expressing Models. Journal of Medicinal Chemistry, 2012, 55, 8364-8374.	2.9	13
45	[111In-DOTA]Somatostatin-14 analogs as potential pansomatostatin-like radiotracers - first results of a preclinical study. EJNMMI Research, 2012, 2, 25.	1.1	24
46	Comparison of biological stability and metabolism of CCK2 receptor targeting peptides, a collaborative project under COST BM0607. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1426-1435.	3.3	70
47	Comparison of three radiolabelled peptide analogues for CCK-2 receptor scintigraphy in medullary thyroid carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1265-1272.	3.3	76
48	[99mTc]Demotensin 5 and 6 in the NTS1-R-targeted imaging of tumours: synthesis and preclinical results. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 1804-1814.	3.3	37
49	Toward Stable N4-Modified Neurotensins for NTS1-Receptor-Targeted Tumor Imaging with 99mTc. Journal of Medicinal Chemistry, 2006, 49, 4767-4776.	2.9	46
50	Potent Bombesin-like Peptides for GRP-Receptor Targeting of Tumors with 99mTc:â€‰ A Preclinical Study. Journal of Medicinal Chemistry, 2005, 48, 100-110.	2.9	149
51	CCK-2/gastrin receptor-targeted tumor imaging with (99m)Tc-labeled minigastrin analogs. Journal of Nuclear Medicine, 2005, 46, 1727-36.	2.8	72